Contraindications of Rebamipide
Rebamipide has minimal contraindications, with hypersensitivity to the drug being the primary absolute contraindication.
Absolute Contraindications
- Hypersensitivity reactions: Patients with known hypersensitivity to rebamipide or any component of the formulation should not receive this medication 1, 2
Use During Breastfeeding
Rebamipide can be used during breastfeeding, as there is no evidence contraindicating its use in lactating women. The available safety data demonstrates an excellent safety profile with minimal systemic absorption and no documented adverse effects in nursing infants 1, 2.
This stands in contrast to many other gastroprotective agents. For context, while NSAIDs like ibuprofen, indomethacin, and naproxen are considered safe in breastfeeding 3, and most maternal medications are compatible with breastfeeding 4, rebamipide's mucosal protective mechanism (acting locally rather than systemically) further supports its safety profile during lactation.
Important Clinical Context
Rebamipide has an exceptionally favorable safety profile compared to alternative gastroprotective agents:
- Adverse event rate: Approximately 36.1% (range 0-70%), with no serious adverse events recorded in clinical trials 5
- Superior tolerability: Significantly lower withdrawal rates (10.3%) compared to misoprostol (18.6%, p=0.0103) 6
- Fewer gastrointestinal symptoms: Lower total severity scores and reduced antacid requirements compared to misoprostol 6
Common Pitfalls to Avoid
Do not confuse rebamipide contraindications with those of other gastroprotective agents:
- PPIs: Have concerns with long-term use (bone fractures, C. difficile infection, nutrient malabsorption)
- Misoprostol: Absolutely contraindicated in pregnancy due to abortifacient effects
- H2 receptor antagonists: Require dose adjustments in renal impairment
Rebamipide requires no dose adjustment in renal or hepatic impairment and has no documented drug-drug interactions of clinical significance 1, 2.
Practical Application
When prescribing rebamipide:
- Screen only for prior hypersensitivity reactions to the drug
- No routine laboratory monitoring required
- Safe for use in pregnancy (no teratogenic effects documented) 2
- Safe during breastfeeding
- No contraindication in elderly patients
- No contraindication with renal or hepatic disease
This minimal contraindication profile makes rebamipide an attractive alternative to PPIs and misoprostol, particularly for patients requiring long-term NSAID therapy or those with contraindications to standard gastroprotective agents 7, 6, 2.